PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsSemaglutide
Ozempic(semaglutide)
Ozempic, Rybelsus, Wegovy (semaglutide) is a protein pharmaceutical. Semaglutide was first approved as Ozempic on 2017-12-05. It has been approved in Europe to treat diabetes mellitus, obesity, overweight, and type 2 diabetes mellitus. The pharmaceutical is active against glucagon-like peptide 1 receptor.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nutritional and metabolic diseasesD009750
endocrine system diseasesD004700
signs and symptoms pathological conditionsD013568
diagnosisD003933
physiological phenomenaD010829
Trade Name
FDA
EMA
Ozempic, Rybelsus, Wegovy
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Semaglutide
Tradename
Company
Number
Date
Products
OZEMPICNovo NordiskN-209637 RX2017-12-05
4 products, RLD, RS
RYBELSUSNovo NordiskN-213051 RX2019-09-20
6 products, RLD, RS
WEGOVYNovo NordiskN-215256 RX2021-06-04
5 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
ozempicNew Drug Application2024-11-01
rybelsusNew Drug Application2024-12-09
wegovyNew Drug Application2024-11-01
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
SEMAGLUTIDE, WEGOVY, NOVO
2025-12-23NPP
2024-06-04NP
SEMAGLUTIDE, OZEMPIC, NOVO
2025-03-28D-185
2023-01-16I-822
SEMAGLUTIDE, RYBELSUS, NOVO
2023-01-16M-252
Patent Expiration
Patent
Expires
Flag
FDA Information
Semaglutide, Wegovy, Novo
113181912041-02-17DPU-3162
108886052038-08-24DPU-3162
97640032033-06-21U-3161
Semaglutide, Rybelsus, Novo
102789232034-05-02U-2628
109331202033-03-15DP
92781232031-12-16DPU-2628
100860472031-12-16DP
109600522031-12-16DP
113829572031-12-16DP
Semaglutide, Ozempic, Novo
103354622033-06-21DPU-2580
91322392032-02-01DP
81293432031-12-05DS, DPU-2202, U-2628, U-3355, U-3469
94571542027-09-29DP
96876112027-02-27DP
RE463632026-08-03DP
89203832026-07-17DP
97759532026-07-17DP
102201552026-07-17DP
110970632026-07-17DP
85361222026-03-20DS, DPU-2202, U-2628, U-3355, U-3469
91080022026-01-20DP
96161802026-01-20DP
98617572026-01-20DP
103576162026-01-20DP
103766522026-01-20DP
113116792026-01-20DP
86849692025-10-20DP
114464432025-10-20DP
81148332025-08-13DP
77629942024-05-23DP
85798692023-06-30DP
ATC Codes
A: Alimentary tract and metabolism drugs
— A10: Drugs used in diabetes
— A10B: Blood glucose lowering drugs, excl. insulins
— A10BJ: Glucagon-like peptide-1 (glp-1) analogues
— A10BJ06: Semaglutide
HCPCS
No data
Clinical
Clinical Trials
475 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 2 diabetes mellitusD003924EFO_0001360E11429531236152
Diabetes mellitusD003920HP_0000819E08-E13409521036147
ObesityD009765EFO_0001073E66.9166314461
Healthy volunteers/patients———412—1—44
OverweightD050177—E66.3124191339
Non-alcoholic fatty liver diseaseD065626EFO_0003095K75.812612—11
Fatty liverD005234EFO_0003934—2512—10
Liver diseasesD008107HP_0002910K70-K7712—1—4
AlbuminuriaD000419EFO_0004285R80.9——11—2
Prediabetic stateD011236EFO_1001121R73.03——11—2
Show 7 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Nutrition disordersD009748EFO_0001069—212——5
Alcoholic fatty liverD005235—K70.0131——5
Chronic renal insufficiencyD051436—N18—22——4
Kidney diseasesD007674EFO_0003086N08—22——4
Alzheimer diseaseD000544EFO_0000249F03——3——3
Weight lossD015431HP_0001824———1—12
Heart failureD006333HP_0001635I50——2——2
DiseaseD004194EFO_0000408R69——1——1
Peripheral arterial diseaseD058729EFO_0004265———1——1
Peripheral vascular diseasesD016491EFO_0003875I73.9——1——1
Show 5 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Digestive system diseasesD004066HP_0011024K92.921———3
Weight gainD015430HP_0004324——1———1
Endometrial hyperplasiaD004714—N85.0—1———1
HyperplasiaD006965EFO_0000536——1———1
MucositisD052016EFO_1001898——1———1
Type 1 diabetes mellitusD003922EFO_0001359E10—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Renal insufficiencyD051437HP_0000083N192————2
Gastrointestinal diseasesD005767——1————1
Hepatic insufficiencyD048550——1————1
HypercholesterolemiaD006937HP_0003124—1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PregnancyD011247EFO_0002950Z33.1————22
CarcinomaD002277—C80.0————11
Thyroid neoplasmsD013964EFO_0003841—————11
Neuroendocrine carcinomaD018278——————11
Papillary thyroid cancerD000077273——————11
Thyroid diseasesD013959HP_0000820E00-E07————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSemaglutide
INNsemaglutide
Description
Semaglutide is a polypeptide that contains a linear sequence of 31 amino acids joined together by peptide linkages. It is an agonist of glucagon-like peptide-1 receptors (GLP-1 AR) and used for the treatment of type 2 diabetes. It has a role as a hypoglycemic agent, a glucagon-like peptide-1 receptor agonist, an anti-obesity agent, a neuroprotective agent and an appetite depressant. It is a polypeptide and a lipopeptide.
Classification
Protein
Drug classpeptides: glucagon-like peptide (GLP) analogs
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID910463-68-2
RxCUI—
ChEMBL IDCHEMBL2108724
ChEBI ID—
PubChem CID56843331
DrugBankDB13928
UNII ID53AXN4NNHX (ChemIDplus, GSRS)
Target
Agency Approved
GLP1R
GLP1R
Organism
Homo sapiens
Gene name
GLP1R
Gene synonyms
NCBI Gene ID
2740
Protein name
glucagon-like peptide 1 receptor
Protein synonyms
GLP-1 receptor, GLP1 receptor, seven transmembrane helix receptor
Uniprot ID
Q99669
Mouse ortholog
Glp1r (14652)
glucagon-like peptide 1 receptor (Q1JQR8)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Wegovy – Novo Nordisk
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Ozempic – Novo Nordisk
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Rybelsus – Novo Nordisk
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Semaglutide
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 7,648 documents
View more details
Safety
Black-box Warning
Black-box warning for: Ozempic, Rybelsus, Wegovy
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
38,700 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use